Critical Appraisal of Serum Urate Targets in the Management of Gout
Overview
Authors
Affiliations
Gout management involves two broad aspects: treatment of gout flares to provide rapid symptomatic relief and long-term urate-lowering therapy to lower serum urate sufficiently to prevent gout flares from occurring. All of the major rheumatology societies recommend a target serum urate of <5 mg/dl (<0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l), both of which are below the point of saturation for urate and therefore lead to monosodium urate crystal dissolution. In this Review, we describe the rationale for treat-to-target urate approach in the long-term management of gout and the current evidence and controversy around the appropriate serum urate targets.
Massimo G, Dyson N, Olotu F, Khambata R, Ahluwalia A Antioxidants (Basel). 2025; 13(12.
PMID: 39765766 PMC: 11672463. DOI: 10.3390/antiox13121439.
Chen Y, Chen Z, Wang W, Hua Y, Ji M Research (Wash D C). 2024; 7:0373.
PMID: 38803506 PMC: 11128648. DOI: 10.34133/research.0373.
Predictors of Inadequate Serum Urate Response to Low-Dose Febuxostat in Male Patients with Gout.
Sun W, Zhao X, Dalbeth N, Terkeltaub R, Cui L, Liu Z J Inflamm Res. 2024; 17:2657-2668.
PMID: 38707960 PMC: 11069377. DOI: 10.2147/JIR.S458250.
Bech-Drewes A, Bonnesen K, Hauge E, Schmidt M Rheumatol Int. 2024; 44(6):1061-1069.
PMID: 38581450 PMC: 11108875. DOI: 10.1007/s00296-024-05584-7.
Gut-immunity-joint axis: a new therapeutic target for gouty arthritis.
Chen P, Luo Z, Lu C, Jian G, Qi X, Xiong H Front Pharmacol. 2024; 15:1353615.
PMID: 38464719 PMC: 10920255. DOI: 10.3389/fphar.2024.1353615.